Altimmune (ALT) to Release Quarterly Earnings on Tuesday

Altimmune (NASDAQ:ALT) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the company earned ($0.32) earnings per share. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Trading Up 1.3 %

Shares of Altimmune stock traded up $0.09 during mid-day trading on Tuesday, hitting $6.88. 1,193,854 shares of the stock were exchanged, compared to its average volume of 3,766,829. Altimmune has a twelve month low of $2.32 and a twelve month high of $14.84. The stock has a market capitalization of $488.96 million, a price-to-earnings ratio of -4.19 and a beta of 0.09. The company has a 50-day simple moving average of $6.76 and a 200 day simple moving average of $6.85.

Analyst Ratings Changes

ALT has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. B. Riley reiterated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Finally, Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.80.

Insider Activity at Altimmune

In related news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.10% of the stock is currently owned by insiders.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.